Treating Vertebrobasilar Ischemia with 3 Different Therapeutic Regimens:Cost-Effectiveness Analysis
- VernacularTitle:3种用药方案治疗椎基底动脉供血不足的成本-效果分析
- Author:
Xinping WANG
- Publication Type:Journal Article
- Keywords:
Vertebrobasilar ischemia;
Therapeutic regimen;
Cost-effectiveness analysis
- From:
China Pharmacy
2005;0(17):-
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To evaluate the therapeutic effects and cost-effectiveness of 3 therapeutic regimens in the treatment of vertebrobasilar ischemia. METHODS: 90 cases with vertebrobasilar ischemia were randomly divided into 3 groups: Group A were assigned to receive buflomedil+Flunarizine, Group B to receive Shuxuening + Flunarizine and Group C to receive compound Compound Danshen + Flunarizine. The curative effects and the cost-effectiveness of the 3 Groups after 14-day treatment were analyzed comparatively. RESULTS: The total costs for Group A, B and C were 1 705.06 yuan,2 876.30 yuan and 1 117.34 yuan, respectively; the effective rates were 93.75%, 92.86% and 70.00%, respectively; the cost-effectiveness ratios were 1 818.73, 3 097.46 and 1 596.20, respectively. As compared with Group C, the incremental costs-effectiveness ratios for Group A and Group B were 2 474.61 and 7 694.49, respectively. CONCLUSION: Group A is more preferable among the 3 therapeutic regimens in terms of cost-effectiveness.
